US0311621009
© PR Newswire
12.12.2025
AMGN
LISTED
NASDAQ
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
News Preview
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMGTHOUSAND OAKS, Calif., Dec. 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdo...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
News Preview
THOUSAND OAKS, Calif., Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The dividend will be paid on March 6, 2026, to all stockholders of record as of the close of business on February 13, 2026.About Amgen Amgen discovers, develops, ma...
Themefolio
Profiler
Peergroup
© PR Newswire
24.11.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the con...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
24.11.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
News Preview
THOUSAND OAKS, Calif., Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference at 10:00 a.m. ET on December 3, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
19.11.2025
AMGN
LISTED
NASDAQ
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
News Preview
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy
Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small Cell Lung Cancer That Has Progressed...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
AMGN
LISTED
NASDAQ
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
News Preview
Study Also Shows 36% Reduction in Risk of Heart Attack
Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNew...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
AMGN
LISTED
NASDAQ
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.
"We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're having on...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
News Preview
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The dividend will be paid on December 12, 2025, to all stockholders of record as of the close of business on November 21, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2025
AMGN
LISTED
NASDAQ
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
News Preview
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke
Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
AMGN
LISTED
NASDAQ
Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amgen Inc. (NASDAQ: AMGN) breached their fiduciary duties to shareholders.
If you currently own Amgen stock and acquired shares on or before July 29, 2020, you may be able to seek corporate governance reforms, the return of funds back to the...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
AMGN
LISTED
NASDAQ
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
News Preview
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation
THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
06.10.2025
AMGN
LISTED
NASDAQ
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
News Preview
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows lan...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
AMGN
LISTED
NASDAQ
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
News Preview
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone
Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovasc...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
News Preview
THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologi...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
AMGN
LISTED
NASDAQ
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
News Preview
THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic de...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen,...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
AMGN
LISTED
NASDAQ
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
News Preview
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs
THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California.
The cent...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
AMGN
LISTED
NASDAQ
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
News Preview
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), common...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
News Preview
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The dividend will be paid on September 12, 2025, to all stockholders of record as of the close of business on August 22, 2025.
About Amgen Amgen discovers, develop...
Themefolio
Profiler
Peergroup
© PR Newswire
31.07.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., July 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
News Preview
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone
THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
AMGN
LISTED
NASDAQ
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
News Preview
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks
In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements...
Themefolio
Profiler
Peergroup
© PR Newswire
18.06.2025
AMGN
LISTED
NASDAQ
AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
News Preview
MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes
New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes
Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT
THOUSAND O...
Themefolio
Profiler
Peergroup
© PR Newswire
13.06.2025
AMGN
LISTED
NASDAQ
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
News Preview
The Making of a Heart Attack Educates Viewers About High LDL-C—a Major, but Modifiable, Risk Factor for Heart Attack and Stroke
THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United Stat...
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
AMGN
LISTED
NASDAQ
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
News Preview
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy
Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine
THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeL...
Themefolio
Profiler
Peergroup
© PR Newswire
30.05.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 4, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, will present...
Themefolio
Profiler
Peergroup
© PR Newswire
16.05.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet...
Themefolio
Profiler
Peergroup
© PR Newswire
09.05.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Wednesday, May 14, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and c...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the c...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO
News Preview
Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs
THOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion....
Themefolio
Profiler
Peergroup
© PR Newswire
11.04.2025
AMGN
LISTED
NASDAQ
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
News Preview
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy
THOUSAND OAKS, Calif., April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatme...
Themefolio
Profiler
Peergroup
© PR Newswire
03.04.2025
AMGN
LISTED
NASDAQ
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
News Preview
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo
UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in the MITIGATE Trial
Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-R...
Themefolio
Profiler
Peergroup
© PR Newswire
13.03.2025
AMGN
LISTED
NASDAQ
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
News Preview
Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing*
Late-Breaking Data to be Presented at AAN 2025
THOUSAND OAKS, Calif., March 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cd...
Themefolio
Profiler
Peergroup
© PR Newswire
08.03.2025
AMGN
LISTED
NASDAQ
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
News Preview
Ongoing Studies are Evaluating Long-Term Maintenance and Durability
THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing...
Themefolio
Profiler
Peergroup
© PR Newswire
08.03.2025
AMGN
LISTED
NASDAQ
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
News Preview
Ongoing Studies are Evaluating Long-Term Maintenance and Durability
THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancin...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
News Preview
THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on June 6, 2025, to all stockholders of record as of the close of business on May 16, 2025.
About Amgen Amgen discovers, develops, manu...
Themefolio
Profiler
Peergroup
© PR Newswire
01.03.2025
AMGN
LISTED
NASDAQ
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
News Preview
Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery
Data Published in NEJM and Presented at AAAAI/WAO 2025
THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezep...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
AMGN
LISTED
NASDAQ
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
News Preview
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being discussed among oncology experts around the world. Recently, the New York Times put out a...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
AMGN
LISTED
NASDAQ
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
News Preview
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Feb. 27, 2025 /CNW/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being discussed among oncology experts around the world. Recently, the New York Times put out a report...
Themefolio
Profiler
Peergroup
© PR Newswire
14.02.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
News Preview
THOUSAND OAKS, Calif., Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the inter...
Themefolio
Profiler
Peergroup
© PR Newswire
07.02.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
News Preview
THOUSAND OAKS, Calif., Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025. Narimon Honarpour, senior vice president of global development at Amgen, will present at the conference. The webcast will be broadcast over the inter...
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
AMGN
LISTED
NASDAQ
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapi...
Themefolio
Profiler
Peergroup
© PR Newswire
01.02.2025
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Part...
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2025
AMGN
LISTED
NASDAQ
EUROPÄISCHE KOMMISSION GENEHMIGT BLINCYTO® BEI PHILADELPHIA-CHROMOSOM-NEGATIVER CD19-POSITIVER B-ZELL-VORLÄUFER-AKUTER LYMPHOBLASTISCHER LEUKÄMIE IN DER KONSOLIDIERUNGSPHASE
News Preview
BLINCYTO wurde zusätzlich zu einer mehrphasigen konsolidierenden Chemotherapie eingesetzt und senkte das Sterberisiko im Vergleich zu einer Chemotherapie allein erheblich
THOUSAND OAKS, Kalifornien., 31. Januar 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) gab heute bekannt, dass die Europäische Kommission (EK) die Monotherapie BLINCYTO®(Blinatumomab)...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2025
AMGN
LISTED
NASDAQ
EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE
News Preview
BLINCYTO Added to Multiphase Consolidation Chemotherapy Significantly Reduced the Risk of Death Versus Chemotherapy Alone
THOUSAND OAKS, Calif., Jan. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy for the treatment of...
Themefolio
Profiler
Peergroup
© PR Newswire
17.01.2025
AMGN
LISTED
NASDAQ
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
News Preview
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC
THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatme...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
News Preview
THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025, to all stockholders of record as of the close of business on February 14, 2025.
About AmgenAmgen discovers, develops, ma...
Themefolio
Profiler
Peergroup
© PR Newswire
07.12.2024
AMGN
LISTED
NASDAQ
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
News Preview
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%
THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cance...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
News Preview
Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M Commitment
THOUSAND OAKS, Calif., Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Spr...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday, Dec. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at...
Themefolio
Profiler
Peergroup
© PR Newswire
29.11.2024
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
News Preview
THOUSAND OAKS, Calif., Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific of...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
News Preview
MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight
MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study
In People With Type 2 Diabetes Living With Obesity or Overweight Ma...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
AMGN
LISTED
NASDAQ
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
News Preview
THOUSAND OAKS, Calif., Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amg...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
AMGN
LISTED
NASDAQ
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
News Preview
Howard Chang, M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer
THOUSAND OAKS, Calif., Nov. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Howard Chang, M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024. Chang will also assume the title and respon...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
AMGN
LISTED
NASDAQ
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
News Preview
MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA® as the First Potential Treatment tor IgG4-RD
Phase 4 AGILE Data Support Shortening KRYSTEXXA® Infusion Time
THOUSAND OAKS, Calif., Nov. 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2024
AMGN
LISTED
NASDAQ
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
News Preview
THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.
"As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not s...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2024
AMGN
LISTED
NASDAQ
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
News Preview
THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneousl...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
